Please assess the completion status of the following clinical trial:

Trial Title: Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older.~2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.~3. Childs class of A or B (up to 9).~4. Hepatocellular carcinoma (HCC) is unresectable with liver-predominant disease or subject has HCC and refused surgery or subject is diagnosed hepatic metastases from any solid tumor. (Multifocal HCC is acceptable, no diffuse HCC).~5. Subject is voluntarily participating in the study and has signed the informed consent.~Exclusion Criteria:~1. Contraindications to doxorubicin, cisplatin, or mytomycin-c administration (or specific mixture of chemotherapy drugs to be used).~2. Evidence of severe or uncontrolled systemic diseases.~3. Congestive cardiac failure \>NYHA class 2 MI within 6 months, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial.~4. Known allergy to Lipiodol (Ethiodol), poppy seed oil, or iodinated contrast agents (that cannot be adequately mitigated with pre-procedure medication).~5. Main portal vein thrombosis is excluded; segmental or branch portal vein thrombosis is acceptable.~6. Subject is breastfeeding.~7. Subject is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lipiodol (Type: OTHER): Lipiodol, 10cc per TACE.

Based on this trial design, predict the completion outcome and termination type (if applicable).